Methods for detecting and for treating pancreatic cancer
AssigneesVan Andel Research Institute, University of Pittsburgh
InventorsBrian B. Haab, Randall E. Brand
Life of this patent
Estimating the term…
Abstract
A method of diagnosing pancreatic cancer in a patient by detecting a level of one or more glycoforms of a Lewis antigen and a level of the one or more glycoforms of MUC5AC. The patient diagnosed with pancreatic cancer then may be treated for this disease. Also, a method for detecting a level of a glycan in a sample which includes using a capture reagent to immobilize the glycan on a substrate; exposing the immobilized glycan to a detection reagent; detecting the level of the immobilized glycan; and combining the biological sample with one or more pre-capture enzymes and/or exposing the immobilized glycan to one or more pre-detection enzymes.
Claims19
A method of diagnosing and treating pancreatic cancer in a subject, said method comprising:
- obtaining or having obtained a biological sample from the human subject, wherein said biological sample includes two or more glycoforms of a Lewis A antigen and wherein the two or more glycoforms of the Lewis A antigen are selected from the group consisting of sialyl-Lewis A:sialyl-Lewis A (sLeA:sLeA), sialyl-Lewis A:type1type2 sialyl-N-acetyl-lactosamine (sLeA:sLacNAc t1t2), sialyl-Lewis A:sulfated Lewis A (sLeA:sulfo-LeA), sialyl-Lewis A:sulfated sialyl-Lewis A (sLeA:sulfo-sLeA), sialyl-Lewis A:sulfated Lewis X (sLeA:sulfo-LeX), and sialyl-Lewis A:sulfated sialyl-Lewis X (sLeA:sulfo-sLeX);
- detecting or having detected a level of the two or more glycoforms of the Lewis A antigen in the biological sample;
- diagnosing the subject with pancreatic cancer when the two or more glycoforms of the Lewis A antigen in the biological sample are elevated as compared to a statistically validated threshold for the two or more glycoforms of the Lewis A antigen;
- and
- administering a therapeutically effective amount of a treatment for pancreatic cancer to the diagnosed subject,
- wherein the treatment is surgically resecting a pancreatic cystic lesion in the subject, applying radiation to the pancreatic cystic lesion, or administering a chemotherapeutic agent to the subject.
A method of providing medical services for a human patient suspected of having or having pancreatic cancer, said method comprising:
- requesting a biological sample from and diagnostic information about the patient, wherein the diagnostic information is a level of two or more glycoforms of a Lewis A antigen in the biological sample and wherein the two or more glycoforms of the Lewis A antigen are selected from the group consisting of sialyl-Lewis A:sialyl-Lewis A (sLeA:sLeA), sialyl-Lewis A:type1type 2 sialyl-N-acetyl-lactosamine (sLeA:sLacNAc t1t2), sialyl-Lewis A:sulfated Lewis A (sLeA:sulfo-LeA), sialyl-Lewis A:sulfated sialyl-Lewis A (sLeA:sulfo-sLeA), sialyl-Lewis A:sulfated Lewis X (sLeA:sulfo-LeX), and sialyl-Lewis A:sulfated sialyl-Lewis X (sLeA:sulfo-sLeX);
- and
- administering a therapeutically effective amount of a treatment for pancreatic cancer when the diagnostic information indicates that the level of the two or more glycoforms of the Lewis A antigen in the biological sample are at an elevated level as compared to control levels of the two or more glycoforms of the Lewis A antigen,
- wherein the treatment is surgically resecting a pancreatic cystic lesion in the subject, applying radiation to the pancreatic cystic lesion, or administering a chemotherapeutic agent to the subject.
Dependencies are inferred from the claim text.